Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q01973
UPID:
ROR1_HUMAN
Alternative names:
Neurotrophic tyrosine kinase, receptor-related 1
Alternative UPACC:
Q01973; Q5VVX6; Q66K77; Q92776
Background:
Inactive tyrosine-protein kinase transmembrane receptor ROR1, alternatively known as Neurotrophic tyrosine kinase, receptor-related 1, exhibits low kinase activity, suggesting its non-kinase role in vivo. It serves as a receptor for WNT5A, activating the NFkB signaling pathway, which may inhibit WNT3A-mediated signaling. Crucially, it supports the innervation of auditory hair cells by spiral ganglion neurons.
Therapeutic significance:
ROR1's involvement in autosomal recessive deafness, 108, highlights its potential as a therapeutic target. Understanding the role of ROR1 could open doors to potential therapeutic strategies for sensorineural hearing loss.